Addex Therapeutics (ADXN) Competitors $9.28 +0.15 (+1.59%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. ESLA, XLO, LVTX, LTRN, SCLX, RNTX, BRNS, MDCX, KZR, and RVPHShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Estrella Immunopharma (ESLA), Xilio Therapeutics (XLO), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Scilex (SCLX), Rein Therapeutics (RNTX), Barinthus Biotherapeutics (BRNS), Medicus Pharma (MDCX), Kezar Life Sciences (KZR), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Estrella Immunopharma Xilio Therapeutics LAVA Therapeutics Lantern Pharma Scilex Rein Therapeutics Barinthus Biotherapeutics Medicus Pharma Kezar Life Sciences Reviva Pharmaceuticals Addex Therapeutics (NASDAQ:ADXN) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Do institutionals & insiders hold more shares of ADXN or ESLA? 16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, ADXN or ESLA? Addex Therapeutics has higher revenue and earnings than Estrella Immunopharma. Addex Therapeutics is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$460K21.37$8.02M-$0.34-27.28Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.55 Does the media favor ADXN or ESLA? In the previous week, Addex Therapeutics had 4 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Addex Therapeutics and 0 mentions for Estrella Immunopharma. Addex Therapeutics' average media sentiment score of 0.45 beat Estrella Immunopharma's score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Addex Therapeutics Neutral Estrella Immunopharma Neutral Which has more risk and volatility, ADXN or ESLA? Addex Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Do analysts rate ADXN or ESLA? Addex Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 223.45%. Estrella Immunopharma has a consensus target price of $16.00, indicating a potential upside of 1,631.60%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ADXN or ESLA more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to Estrella Immunopharma's net margin of 0.00%. Addex Therapeutics' return on equity of -54.27% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Addex Therapeutics3,584.49% -54.27% -49.15% Estrella Immunopharma N/A -1,132.38%-273.91% SummaryAddex Therapeutics beats Estrella Immunopharma on 9 of the 13 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.67M$2.44B$5.53B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio-27.288.8627.4020.24Price / Sales21.37678.05419.60118.25Price / CashN/A157.0736.6357.47Price / Book0.894.638.085.67Net Income$8.02M$31.34M$3.16B$248.47M7 Day Performance3.52%3.25%2.84%3.32%1 Month Performance14.86%6.80%3.69%5.20%1 Year Performance18.30%1.89%35.30%21.35% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.7357 of 5 stars$9.28+1.6%$30.00+223.5%+18.3%$9.67M$460K-27.2830ESLAEstrella Immunopharma2.2438 of 5 stars$0.92-7.1%$16.00+1,639.1%-19.7%$35.80MN/A-3.54N/AGap UpXLOXilio Therapeutics2.2182 of 5 stars$0.67-2.7%$4.00+497.0%-19.7%$35.65M$6.34M-0.8070News CoveragePositive NewsLVTXLAVA Therapeutics1.8584 of 5 stars$1.33+1.1%$3.17+139.0%-25.8%$34.46M$11.98M-1.2760LTRNLantern Pharma1.5629 of 5 stars$3.07-3.5%$25.00+714.3%-25.9%$34.30MN/A-1.6720News CoverageGap DownSCLXScilex1.7492 of 5 stars$4.98+1.4%$455.00+9,036.5%-90.5%$34.13M$56.59M-0.1780RNTXRein TherapeuticsN/A$1.50-2.6%N/AN/A$34.12MN/A-0.529BRNSBarinthus Biotherapeutics2.8336 of 5 stars$0.89+5.7%$6.25+603.0%-31.8%$33.93M$14.97M-0.54107News CoverageGap UpMDCXMedicus Pharma1.8692 of 5 stars$2.34-6.0%$23.50+904.3%N/A$33.80MN/A-2.02N/AAnalyst ForecastKZRKezar Life Sciences4.1799 of 5 stars$4.26-5.8%$39.50+827.2%-21.3%$33.02M$7M-0.3960Gap DownRVPHReviva Pharmaceuticals2.1372 of 5 stars$0.69-1.1%$9.00+1,196.1%-65.6%$32.80MN/A-0.885Gap Up Related Companies and Tools Related Companies Estrella Immunopharma Alternatives Xilio Therapeutics Alternatives LAVA Therapeutics Alternatives Lantern Pharma Alternatives Scilex Alternatives Rein Therapeutics Alternatives Barinthus Biotherapeutics Alternatives Medicus Pharma Alternatives Kezar Life Sciences Alternatives Reviva Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADXN Stock Alerts